CNTX
Context Therapeutics Inc. NASDAQ Listed Oct 20, 2021$0.58
+3.57%
vs $0.56
Mkt Cap $55.2M
52w Low $0.56
0.7% of range
52w High $3.36
50d MA $1.97
200d MA $1.78
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-59.7%
P/FCF
-2.1x
RSI (14)
5.60
ATR (14)
$0.14
Beta
1.83
50d MA
$1.97
200d MA
$1.78
Avg Volume
2.7M
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
2001 Market Street · Philadelphia, PA 19103 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.11 | -0.14 | -27.3% | 2.99 | +0.0% | -3.7% | +4.9% | +5.3% | -16.0% | -4.9% | — |
| Nov 5, 2025 | AMC | -0.09 | -0.10 | -11.1% | 1.13 | -1.8% | -5.3% | +4.7% | +7.1% | -0.8% | -0.8% | — |
| Aug 6, 2025 | AMC | -0.06 | -0.09 | -50.0% | 0.70 | +0.8% | +0.0% | +3.0% | -5.9% | +0.4% | +2.9% | — |
| May 7, 2025 | AMC | -0.05 | -0.05 | +0.0% | 0.77 | +9.8% | +0.0% | +1.0% | -0.1% | +5.1% | -3.7% | — |
| Mar 20, 2025 | AMC | -0.05 | -0.04 | +20.0% | 0.77 | -0.0% | +0.2% | -1.0% | +13.2% | -8.6% | -6.9% | — |
| Nov 6, 2024 | AMC | -0.11 | -0.22 | -100.0% | 2.22 | +1.4% | -5.9% | -6.7% | +4.6% | +0.5% | -3.9% | — |
| Aug 7, 2024 | AMC | -0.08 | -0.04 | +50.0% | 2.34 | +1.3% | +2.6% | -4.6% | +4.4% | +0.0% | +8.8% | — |
| May 8, 2024 | AMC | -0.38 | -0.23 | +39.5% | 1.81 | +0.6% | +1.1% | +2.2% | -10.2% | +1.8% | -1.2% | — |
| Mar 21, 2024 | AMC | -0.35 | -0.42 | -20.0% | 1.07 | +1.9% | +9.3% | +7.7% | +0.8% | +8.7% | +0.0% | — |
| Nov 9, 2023 | AMC | -0.30 | -0.37 | -23.3% | 1.08 | +0.4% | -2.0% | -1.2% | -3.8% | +0.5% | -0.5% | — |
| Aug 9, 2023 | AMC | -0.20 | -0.31 | -55.0% | 0.94 | +0.0% | +10.6% | +10.6% | +2.6% | +3.4% | -9.0% | — |
| May 10, 2023 | AMC | -0.19 | -0.40 | -110.5% | 0.62 | -3.2% | -6.4% | -4.1% | -11.4% | +7.5% | +3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.02 | $3.28 | +8.6% | +5.3% | -16.0% | -4.9% | +2.0% | -5.4% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $3.02 | $3.28 | +8.6% | +5.3% | -16.0% | -4.9% | +2.0% | -5.4% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $3.02 | $3.28 | +8.6% | +5.3% | -16.0% | -4.9% | +2.0% | -5.4% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.11 | -1.8% | -5.3% | +4.7% | +7.1% | -0.8% | -0.8% |
| Nov 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.13 | $1.11 | -1.8% | -5.3% | +4.7% | +7.1% | -0.8% | -0.8% |
| Oct 16 | D. Boral Capital | Maintains | Buy → Buy | — | $1.34 | $1.36 | +1.5% | -6.0% | +14.3% | -4.9% | -7.3% | -4.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.70 | $0.70 | +0.8% | +0.0% | +3.0% | -5.9% | +0.4% | +2.9% |
| Aug 7 | D. Boral Capital | Maintains | Buy → Buy | — | $0.70 | $0.70 | +0.8% | +0.0% | +3.0% | -5.9% | +0.4% | +2.9% |
| Jun 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.65 | $0.64 | -2.3% | -0.5% | +1.4% | -0.8% | -4.2% | +0.7% |
| May 8 | D. Boral Capital | Maintains | Buy → Buy | — | $0.77 | $0.85 | +9.8% | +0.0% | +1.0% | -0.1% | +5.1% | -3.7% |
| Apr 29 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | -0.0% | -6.3% | -1.5% | -0.5% | +0.8% | -3.6% |
| Apr 9 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.67 | -0.1% | +0.1% | +1.4% | +14.8% | +9.6% | -1.4% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.77 | $0.77 | -0.0% | +0.2% | -1.0% | +13.2% | -8.6% | -6.9% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $0.77 | $0.77 | -0.0% | +0.2% | -1.0% | +13.2% | -8.6% | -6.9% |
| Jan 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.99 | $1.03 | +4.0% | -1.0% | -0.2% | +3.2% | -3.5% | -3.7% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.26 | $2.25 | -0.4% | -8.0% | -5.8% | -1.5% | -4.1% | +0.5% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.09 | $2.04 | -2.4% | -0.5% | +0.0% | -5.8% | +13.8% | +1.3% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.94 | $2.05 | +5.7% | +3.1% | +1.0% | +0.0% | +8.9% | -0.5% |
| May 9 | Maxim Group | Maintains | Buy → Buy | — | $1.81 | $1.82 | +0.6% | +1.1% | +2.2% | -10.2% | +1.8% | -1.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.81 | $1.82 | +0.6% | +1.1% | +2.2% | -10.2% | +1.8% | -1.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.16 | +0.9% | -7.0% | +9.3% | +7.7% | +0.8% | +8.7% |
| Nov 1 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.06 | $1.14 | +7.5% | +4.7% | +13.5% | -0.8% | -1.6% | -4.9% |
| Jun 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.12 | $1.11 | -0.9% | +15.2% | +8.5% | -6.4% | -6.1% | +2.4% |
| Mar 23 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.66 | $0.60 | -9.1% | -7.6% | +1.7% | +4.1% | -9.4% | +3.4% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.96 | $0.98 | +2.1% | +0.9% | -5.0% | -3.2% | -4.5% | -1.1% |
| Feb 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.14 | $2.18 | +1.9% | +9.8% | -5.5% | +0.5% | -7.6% | -2.4% |
| Jan 24 | ThinkEquity | Maintains | Buy → Buy | — | $2.10 | $1.99 | -5.2% | +6.7% | +1.8% | -7.5% | -7.6% | -0.5% |
No insider trades available.
8-K · 5.03
! Medium
Context Therapeutics Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 26
8-K · 8.01
!! High
Context Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Context Therapeutics announced positive interim Phase 1 results for CTIM-76, a Claudin 6-targeted bispecific antibody, supporting continued development of this potentially transformative cancer immunotherapy candidate.
Jun 15
8-K · 1.01
!! High
Context Therapeutics Inc. -- 8-K 1.01: License Agreement
Context Therapeutics licensed technology to BioAtla for $4.5 million, providing CNTX with upfront cash while diversifying revenue streams through strategic partnerships.
May 18
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Context Therapeutics filed an 8-K on April 2, 2026, indicating a material event requiring disclosure, though specific details are unavailable; investors should monitor for subsequent filings clarifying the announcement's business impact.
Apr 2
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CNTX's 8-K filing contains standard forward-looking statement disclaimers, indicating management is communicating future guidance but cannot guarantee results, so investors should exercise caution when evaluating the company's projections.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CNTX resolved ongoing litigation with prejudice, eliminating legal liability risk and clearing a potential overhang on shareholder value before the June annual meeting.
Mar 13
8-K · 8.01
!! High
Context Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Context Therapeutics resolved a Delaware stockholder class action lawsuit through a proposed consent judgment, dismissing the February 2026 complaint with prejudice and proceeding with its annual meeting as planned.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Mpm Bioimpact Llc | 10,679,391 | $28M | — | Mar 2026 |
| 2 | Soleus Capital Management, L.p. | 6,963,141 | $18M | New | Mar 2026 |
| 3 | Blue Owl Capital Holdings Lp | 5,089,015 | $13M | Reduced | Mar 2026 |
| 4 | Avidity Partners Management Lp | 4,998,267 | $13M | New | Mar 2026 |
| 5 | Franklin Resources Inc | 3,803,338 | $10M | Reduced | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 3,431,953 | $9M | New | Mar 2026 |
| 7 | Marshall Wace, Llp | 2,948,441 | $8M | Added | Mar 2026 |
| 8 | Millennium Management | 1,424,374 | $4M | Reduced | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 1,093,894 | $3M | New | Mar 2026 |
| 10 | Adar1 Capital Management, Llc | 351,094 | $920K | New | Mar 2026 |
| 11 | Woodline Partners Lp | 250,088 | $655K | New | Mar 2026 |
| 12 | Renaissance Technologies Llc | 182,999 | $479K | Reduced | Mar 2026 |
| 13 | Citadel Advisors Llc | 140,017 | $367K | Added | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 114,888 | $301K | Added | Mar 2026 |
| 15 | Pathstone Holdings, Llc | 110,244 | $289K | — | Mar 2026 |
| 16 | Hrt Financial Lp | 104,973 | $275K | New | Mar 2026 |
| 17 | Mill Creek Capital Advisors, Llc | 104,631 | $274K | — | Mar 2026 |
| 18 | Northern Trust Corp | 103,256 | $271K | Added | Mar 2026 |
| 19 | Velan Capital Investment Management Lp | 100,000 | $262K | — | Mar 2026 |
| 20 | Clear Harbor Asset Management, Llc | 92,804 | $243K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Franklin Biotechnology Discovery Fund | 1,479,200 | $4M | Jan 2026 |
| 2 | Fidelity Extended Market Index Fund | 247,735 | $557K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 97,615 | $220K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 70,420 | $158K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 63,705 | $143K | Feb 2026 |
| 6 | Avantis U.S. Small Cap Equity ETF | 26,383 | $59K | Feb 2026 |
Valuation
Market Cap
$55.2M
Enterprise Value
-$10.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.22x
P/B
0.91x
P/S
—
P/FCF
-2.09x
EV/EBITDA
—
Shares Out
95.2M
Financials (TTM)
Revenue
$0
Net Income
-$40.2M
EBITDA
-$40.2M
Free Cash Flow
-$26.4M
Op Cash Flow
-$26.4M
EPS Basic
$-0.38
EPS Diluted
$-0.42
EPS Forward
$-0.44
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$68.5M
Total Liab.
$8.0M
Total Equity
$60.5M
Cash
$66.0M
LT Debt
$0
Book Value/Sh
$0.64
Debt/Equity
0.00x
Current Ratio
8.52
Quick Ratio
8.52
Returns & Growth
ROE
-59.7%
ROA
-52.7%
ROIC
-65.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+17.4%
Price Returns
2W
+22.3%
1M
+20.8%
3M
+26.7%
6M
+154.5%
12M
+393.8%
Technicals
52W High
$3.36
52W Low
$0.56
50d MA
$1.97
200d MA
$1.78
RSI (14)
5.60
ATR (14)
$0.14
Beta
1.83
Avg Volume
2.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.25
High
$6.00
Low
$4.50
Median
$5.25
Data updated apr 25, 2026 2:22am
· Source: financialmodelingprep.com